The Keap1-Nrf2 Cell Defense Pathway - A Promising Therapeutic Target?

Advances in Pharmacology

Volumn 63, Issue , 2012, Pages 43-79

  Copple, Ian M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antioxidant; Cancer; Cell defense; Disease; Keap1; Nrf2

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; B RAF KINASE; BARDOXOLONE METHYL; BRUSATOL; CARBOPLATIN; CD36 ANTIGEN; CISPLATIN; CULLIN; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HEME OXYGENASE 1; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MICRORNA; MYC PROTEIN; NOTCH1 RECEPTOR; PARACETAMOL; PROTEIN P62; PROTHYMOSIN ALPHA; REACTIVE OXYGEN METABOLITE; RESVERATROL; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

3' UNTRANSLATED REGION; ACTIN FILAMENT; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ARTICLE; AUTOPHAGY; BINDING AFFINITY; BRAIN MALARIA; CANCER RESISTANCE; CARCINOGENESIS; CELL DAMAGE; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHEMICAL STRESS; CHEMOPROPHYLAXIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFORMATIONAL TRANSITION; CONJUGATION; CONSENSUS SEQUENCE; CPG ISLAND; CYTOSOL; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; ELECTROPHILICITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; EPIGENETICS; GENE DELETION; GENE INSERTION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOGENESIS; LIVER CELL; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG EMPHYSEMA; MITOCHONDRIAL RESPIRATION; MOLECULAR INTERACTION; NEGATIVE FEEDBACK; NEOPLASM; NEPHROTOXICITY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOPHILICITY; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN SYNTHESIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRAUMATIC BRAIN INJURY; UBIQUITINATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; XENOBIOTIC METABOLISM;

EID: 84863769005     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398339-8.00002-1     Document Type: Chapter

References (228)

1. Abiko Y., et al. Participation of covalent modification of Keap1 in the activation of Nrf2 by tert-butylbenzoquinone, an electrophilic metabolite of butylated hydroxyanisole. Toxicology and Applied Pharmacology 2011, 255(1):32-39.
2. Ahn Y.H., et al. Electrophilic tuning of the chemoprotective natural product sulforaphane. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(21):9590-9595.
3. Alam J., et al. Heme activates the heme oxygenase-1 gene in renal epithelial cells by stabilizing Nrf2. American Journal of Physiology - Renal Physiology 2003, 284(4):F743-F752.
4. Aleksunes L.M., et al. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. Journal of Pharmacology and Experimental Therapeutics 2010, 335(1):2-12.
5. Baird L., et al. The cytoprotective role of the Keap1-Nrf2 pathway. Archives of Toxicology 2011, 85(4):241-272.
6. Barone M.C., et al. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Disease Models & Mechanisms 2011, 4(5):701-707.
7. Bjelakovic G., et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews 2008, 2:CD007176.
8. Blake D.J., et al. Deletion of Keap1 in the lung attenuates acute cigarette smoke-induced oxidative stress and inflammation. American Journal of Respiratory Cell and Molecular Biology 2010, 42(5):524-536.
9. Bui C.B., et al. Persistent expression of Nqo1 by p62-mediated Nrf2 activation facilitates p53-dependent mitotic catastrophe. Biochemical and Biophysical Research Communications 2011, 412(2):347-352.
10. Burton N.C., et al. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006, 27(6):1094-1100.
11. Calkins M.J., et al. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxidants & Redox Signaling 2009, 11(3):497-508.
12. Cao T.T., et al. Increased nuclear factor-erythroid 2 p45-related factor 2 activity protects SH-SY5Y cells against oxidative damage. Journal of Neurochemistry 2005, 95(2):406-417.
13. Chan J.Y., et al. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochimica et Biophysica Acta 2000, 1517(1):19-26.
14. Chan K., et al. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(8):4611-4616.
15. Chan K., et al. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(24):13943-13948.
16. Chen N., et al. Nrf2 expression in endometrial serous carcinomas and its precancers. International Journal of Clinical and Experimental Pathology 2010, 4(1):85-96.
17. Chen P.C., et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(8):2933-2938.
18. Chen W., et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Molecular Cell 2009, 34(6):663-673.
19. Cheng Q., et al. Constitutive activation of nuclear factor-E2-related factor 2 induces biotransformation enzyme and transporter expression in livers of mice with hepatocyte-specific deletion of Kelch-like ECH-associated protein 1. Journal of Biochemical and Molecular Toxicology 2011, 25(5):320-329.
20. Cho H.Y., et al. Nrf2 protects against airway disorders. Toxicology and Applied Pharmacology 2010, 244(1):43-56.
21. Chowdhry S., et al. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radical Biology & Medicine 2010, 48(2):357-371.
22. Clements C.M., et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(41):15,091-15,096.
23. Copple I.M., et al. The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology 2008, 48(4):1292-1301.
24. Copple I.M., et al. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 2008, 246(1):24-33.
25. Copple I.M., et al. The Keap1-Nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity. Handbook of Experimental Pharmacology 2010, 196:233-266.
26. Copple I.M., et al. Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. Journal of Biological Chemistry 2010, 285(22):16,782-16,788.
27. Cullinan S.B., et al. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Molecular and Cellular Biology 2004, 24(19):8477-8486.
28. Cullinan S.B., et al. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Molecular and Cellular Biology 2003, 23(20):7198-7209.
29. Davies K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000, 50(4, 5):279-289.
30. Deeb D., et al. CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. Anticancer Research 2007, 27(5A):3035-3044.
31. Delaine T., et al. Structure-activity relationship between the in vivo skin sensitizing potency of analogues of phenyl glycidyl ether and the induction of Nrf2-dependent luciferase activity in the keratinosens in vitro assay. Chemical Research in Toxicology 2011, 24(8):1312-1318.
32. DeNicola G.M., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475(7354):106-109.
33. Dhakshinamoorthy S., et al. Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. Journal of Biological Chemistry 2004, 279(19):20,096-20,107.
34. Dinkova-Kostova A.T., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(18):11,908-11,913.
35. Dinkova-Kostova A.T., et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(12):4584-4589.
36. Dinkova-Kostova A.T., et al. An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1. Journal of Biological Chemistry 2010, 285(44):33,747-33,755.
37. Eades G., et al. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. Journal of Biological Chemistry 2011, 286(47):40,725-40,733.
38. Edinger A.L., et al. Death by design: apoptosis, necrosis and autophagy. Current Opinion in Cell Biology 2004, 16(6):663-669.
39. Eggler A.L., et al. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(29):10,070-10,075.
40. Emter R., et al. Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicology and Applied Pharmacology 2010, 245(3):281-290.
41. Enomoto A., et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicological Sciences 2001, 59(1):169-177.
42. Fan W., et al. Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy 2010, 6(5):614-621.
43. Ferreira A., et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell 2011, 145(3):398-409.
44. Filipowicz W., et al. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nature Reviews Genetics 2008, 9(2):102-114.
45. Furukawa M., et al. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Molecular and Cellular Biology 2005, 25(1):162-171.
46. Gan L., et al. Keap1-Nrf2 activation in the presence and absence of DJ-1. European Journal of Neurosciences 2010, 31(6):967-977.
47. Gao L., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. Journal of Biological Chemistry 2007, 282(4):2529-2537.
48. Gartel A.L., et al. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Molecular Cancer Therapeutics 2002, 1(8):639-649.
49. Goldring C.E., et al. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 2004, 39(5):1267-1276.
50. Goven D., et al. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax 2008, 63(10):916-924.
51. Hayes J.D., et al. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends in Biochemical Sciences 2009, 34(4):176-188.
52. Hayes J.D., et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxidants & Redox Signaling 2010, 13(11):1713-1748.
53. Hirota A., et al. Ultraviolet A irradiation induces NF-E2-related factor 2 activation in dermal fibroblasts: protective role in UVA-induced apoptosis. Journal of Investigative Dermatology 2005, 124(4):825-832.
54. Hirota A., et al. Acceleration of UVB-induced photoageing in nrf2 gene-deficient mice. Experimental Dermatology 2011, 20(8):664-668.
55. Hirotsu Y., et al. Nrf2 degron-fused reporter system: a new tool for specific evaluation of Nrf2 inducers. Genes Cells 2011, 16(4):406-415.
56. Holland R., et al. Prospective type 1 and type 2 disulfides of Keap1 protein. Chemical Research in Toxicology 2008, 21(10):2051-2060.
57. Homma S., et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clinical Cancer Research 2009, 15(10):3423-3432.
58. Hong F., et al. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chemical Research in Toxicology 2005, 18(12):1917-1926.
59. Hong F., et al. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. Journal of Biological Chemistry 2005, 280(36):31,768-31,775.
60. Hu C., et al. Modification of keap1 cysteine residues by sulforaphane. Chemical Research in Toxicology 2011, 24(4):515-521.
61. Hubbs A.F., et al. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor nrf2. American Journal of Pathology 2007, 170(6):2068-2076.
62. Iizuka T., et al. Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 2005, 10(12):1113-1125.
63. Itoh K., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and Biophysical Research Communications 1997, 236(2):313-322.
64. Itoh K., et al. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Molecular and Cellular Biology 2004, 24(1):36-45.
65. Itoh K., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes & Development 1999, 13(1):76-86.
66. Itoh K., et al. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 2003, 8(4):379-391.
67. Jain A., et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. Journal of Biological Chemistry 2010, 285(29):22,576-22,591.
68. Jazwa A., et al. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxidants & Redox Signaling 2011, 14(12):2347-2360.
69. Jiang T., et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Research 2010, 70(13):5486-5496.
70. Jin W., et al. Role of Nrf2 in protection against traumatic brain injury in mice. Journal of Neurotrauma 2009, 26(1):131-139.
71. Kalkhoven E. CBP and p300: HATs for different occasions. Biochemical Pharmacology 2004, 68(6):1145-1155.
72. Kang M.I., et al. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(7):2046-2051.
73. Kanninen K., et al. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(38):16,505-16,510.
74. Karapetian R.N., et al. Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications for expression of oxidative stress-protecting genes. Molecular and Cellular Biology 2005, 25(3):1089-1099.
75. Kaspar J.W., et al. An autoregulatory loop between Nrf2 and Cul3-Rbx1 controls their cellular abundance. Journal of Biological Chemistry 2010, 285(28):21,349-21,358.
76. Katoh Y., et al. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 2001, 6(10):857-868.
77. Kay H.Y., et al. Nrf2-mediated liver protection by sauchinone, an antioxidant lignan, from acetaminophen toxicity through the PKCdelta-GSK3beta pathway. British Journal of Pharmacology 2011, 163(8):1653-1665.
78. Kerns M.L., et al. Reprogramming of keratin biosynthesis by sulforaphane restores skin integrity in epidermolysis bullosa simplex. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(36):14,460-14,465.
79. Khor T.O., et al. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochemical Pharmacology 2011, 82(9):1073-1078.
80. Kim J.E., et al. Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. Cellular Signalling 2010, 22(11):1645-1654.
81. Kim R.H., et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(14):5215-5220.
82. Kim Y.R., et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. Journal of Pathology 2010, 220(4):446-451.
83. Kimura S., et al. Essential role of Nrf2 in keratinocyte protection from UVA by quercetin. Biochemical and Biophysical Research Communications 2009, 387(1):109-114.
84. Kitteringham N.R., et al. Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. Journal of Proteomics 2010, 73(8):1612-1631.
85. Klaassen C.D. Xenobiotic transporters: another protective mechanism for chemicals. International Journal of Toxicology 2002, 21(1):7-12.
86. Klaassen C.D., et al. Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicology and Applied Pharmacology 2010, 244(1):57-65.
87. Klose R.J., et al. Genomic DNA methylation: the mark and its mediators. Trends in Biochemical Sciences 2006, 31(2):89-97.
88. Kobayashi A., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Molecular and Cellular Biology 2004, 24(16):7130-7139.
89. Kobayashi A., et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Molecular and Cellular Biology 2006, 26(1):221-229.
90. Kobayashi M., et al. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Molecular and Cellular Biology 2009, 29(2):493-502.
91. Komatsu M., et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nature Cell Biology 2010, 12(3):213-223.
92. Kong X., et al. Enhancing Nrf2 pathway by disruption of keap1 in myeloid leukocytes protects against sepsis. American Journal of Respiratory and Critical Care Medicine 2011, 184(8):928-938.
93. Konopleva M., et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002, 99(1):326-335.
94. Konstantinopoulos P.A., et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Research 2011, 71(15):5081-5089.
95. Krewski D., et al. New directions in toxicity testing. Annual Review of Public Health 2011, 32:161-178.
96. Kurz E.U., et al. Identification of DNA-protein interactions in the 5' flanking and 5' untranslated regions of the human multidrug resistance protein (MRP1) gene: evaluation of a putative antioxidant response element/AP-1 binding site. Biochemical and Biophysical Research Communications 2001, 285(4):981-990.
97. Lau A., et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Molecular and Cellular Biology 2010, 30(13):3275-3285.
98. Lee D.F., et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Molecular Cell 2009, 36(1):131-140.
99. Lee J.M., et al. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. Journal of Biological Chemistry 2003, 278(14):12,029-12,038.
100. Lee O.H., et al. An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance. Journal of Biological Chemistry 2007, 282(50):36,412-36,420.
101. Leung C.K., et al. High-throughput screening and biosensing with fluorescent C. elegans strains. Journal of Visualized Experiments 2011, 51:2745.
102. Levonen A.L., et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochemical Journal 2004, 378(Pt 2):373-382.
103. Li L., et al. Molecular evolution of Keap1. Two Keap1 molecules with distinctive intervening region structures are conserved among fish. Journal of Biological Chemistry 2008, 283(6):3248-3255.
104. Li Q.K., et al. KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. Journal of Human Genetics 2011, 56(3):230-234.
105. Liby K., et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Research 2005, 65(11):4789-4798.
106. Lister A., et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer 2011, 10:37.
107. Liu G., et al. Screening method for the discovery of potential cancer chemoprevention agents based on mass spectrometric detection of alkylated Keap1. Analytical Chemistry 2005, 77(19):6407-6414.
108. Liu G.H., et al. NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochimica et Biophysica Acta 2008, 1783(5):713-727.
109. Liu Y., et al. A genomic screen for activators of the antioxidant response element. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(12):5205-5210.
110. Lloberas J., et al. p21(waf1/CIP1), a CDK inhibitor and a negative feedback system that controls macrophage activation. European Journal of Immunology 2009, 39(3):691-694.
111. Lo S.C., et al. PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex. Journal of Biological Chemistry 2006, 281(49):37,893-37,903.
112. Lo S.C., et al. PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria. Experimental Cell Research 2008, 314(8):1789-1803.
113. Lo S.C., et al. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO Journal 2006, 25(15):3605-3617.
114. Loignon M., et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Molecular Cancer Therapeutics 2009, 8(8):2432-2440.
115. Luo Y., et al. Sites of alkylation of human Keap1 by natural chemoprevention agents. Journal of The American Society for Mass Spectrometry 2007, 18(12):2226-2232.
116. Ma Q., et al. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. American Journal of Pathology 2006, 168(6):1960-1974.
117. Ma X., et al. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemotherapy and Pharmacology 2011.
118. Malhotra D., et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. American Journal of Respiratory and Critical Care Medicine 2008, 178(6):592-604.
119. Mao L., et al. Transcription factor Nrf2 protects the spinal cord from inflammation produced by spinal cord injury. Journal of Surgical Research 2011, 170(1):e105-e115.
120. Mao L., et al. Disruption of Nrf2 exacerbated the damage after spinal cord injury in mice. Journal of Trauma 2011, 72(1):189-198.
121. Matus S., et al. Protein folding stress in neurodegenerative diseases: a glimpse into the ER. Current Opinion in Cell Biology 2011, 23(2):239-252.
122. McMahon M., et al. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. Journal of Biological Chemistry 2003, 278(24):21,592-21,600.
123. McMahon M., et al. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(44):18,838-18,843.
124. McMahon M., et al. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a " tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. Journal of Biological Chemistry 2006, 281(34):24,756-24,768.
125. Miseta A., et al. Relationship between the occurrence of cysteine in proteins and the complexity of organisms. Molecular Biology and Evolution 2000, 17(8):1232-1239.
126. Moi P., et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(21):9926-9930.
127. Moscat J., et al. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009, 137(6):1001-1004.
128. Motohashi H., et al. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 2002, 294(1, 2):1-12.
129. Mulcahy R.T., et al. Constitutive and beta-naphthoflavone-induced expression of the human gamma-glutamylcysteine synthetase heavy subunit gene is regulated by a distal antioxidant response element/TRE sequence. Journal of Biological Chemistry 1997, 272(11):7445-7454.
130. Muscarella L.A., et al. Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics 2011, 6(3):317-325.
131. Muscarella L.A., et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 2011, 6(6):710-719.
132. Toxicity Testing in the 21st Century: A Vision and A Strategy 2007, N.R.C., National Research Council, Washington, DC.
133. Neymotin A., et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology and Medicine 2011, 51(1):88-96.
134. Nguyen T., et al. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. Journal of Biological Chemistry 2003, 278(7):4536-4541.
135. Nioi P., et al. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochemical Journal 2003, 374(Pt 2):337-348.
136. Nioi P., et al. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochemical and Biophysical Research Communications 2007, 362(4):816-821.
137. Nordberg J., et al. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radical Biology and Medicine 2001, 31(11):1287-1312.
138. Oeckinghaus A., et al. Crosstalk in NF-kappaB signaling pathways. Nature Immunology 2011, 12(8):695-708.
139. Ogura T., et al. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(7):2842-2847.
140. Ohnuma T., et al. Activation of the Nrf2/ARE pathway via S-alkylation of cysteine 151 in the chemopreventive agent-sensor Keap1 protein by falcarindiol, a conjugated diacetylene compound. Toxicology and Applied Pharmacology 2010, 244(1):27-36.
141. Ohta T., et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Research 2008, 68(5):1303-1309.
142. Okawa H., et al. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochemical and Biophysical Research Communications 2006, 339(1):79-88.
143. Olagnier D., et al. Nrf2, a PPARgamma alternative pathway to promote CD36 expression on inflammatory macrophages: implication for malaria. PLOS Pathogens 2011, 7(9):e1002254.
144. Osburn W.O., et al. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicological Sciences 2008, 104(1):218-227.
145. Ostapowicz G., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of Internal Medicine 2002, 137(12):947-954.
146. Padmanabhan B., et al. Structural analysis of the complex of Keap1 with a prothymosin alpha peptide. Acta Crystallographica Section F - Structural Biology and Crystallization Communications 2008, 64(Pt. 4):233-238.
147. Padmanabhan B., et al. Structural insights into the similar modes of Nrf2 transcription factor recognition by the cytoplasmic repressor Keap1. Journal of Synchrotron Radiation 2008, 15(Pt. 3):273-276.
148. Padmanabhan B., et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Molecular Cell 2006, 21(5):689-700.
149. Pamplona A., et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nature Medicine 2007, 13(6):703-710.
150. Park B.K., et al. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chemico-Biological Interactions 2011, 192(1, 2):30-36.
151. Pergola P.E., et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. American Journal of Nephrology 2011, 33(5):469-476.
152. Pergola P.E., et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. New England Journal of Medicine 2011, 365(4):327-336.
153. Prestera T., et al. Chemical and molecular regulation of enzymes that detoxify carcinogens. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(7):2965-2969.
154. Rachakonda G., et al. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chemical Research in Toxicology 2008, 21(3):705-710.
155. Ramos-Gomez M., et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(6):3410-3415.
156. Rangasamy T., et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. Journal of Clinical Investigastions 2004, 114(9):1248-1259.
157. Reddy N.M., et al. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene 2008, 27(44):5821-5832.
158. Reichard J.F., et al. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Research 2007, 35(21):7074-7086.
159. Reisman S.A., et al. CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicology and Applied Pharmacology 2009, 236(1):109-114.
160. Reisman S.A., et al. Altered disposition of acetaminophen in Nrf2-null and Keap1-knockdown mice. Toxicological Sciences 2009, 109(1):31-40.
161. Ren D., et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(4):1433-1438.
162. Ryu K., et al. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer 2010, 10:187.
163. Sahin K., et al. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sciences 2010, 87(7, 8):240-245.
164. Sakurai T., et al. Ebselen, a seleno-organic antioxidant, as an electrophile. Chemical Research in Toxicology 2006, 19(9):1196-1204.
165. Sangokoya C., et al. microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 2010, 116(20):4338-4348.
166. Saw C.L., et al. Impact of Nrf2 on UVB-induced skin inflammation/photoprotection and photoprotective effect of sulforaphane. Molecular Carcinogenesis 2011, 50(6):479-486.
167. Schafer M., et al. Nrf2 establishes a glutathione-mediated gradient of UVB cytoprotection in the epidermis. Genes Development 2010, 24(10):1045-1058.
168. Sekhar K.R., et al. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicology and Applied Pharmacology 2010, 244(1):21-26.
169. Sekhar K.R., et al. Inhibition of the 26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase. Biochemical and Biophysical Research Communications 2000, 270(1):311-317.
170. Shapiro S.D. Animal models for chronic obstructive pulmonary disease: age of klotho and marlboro mice. American Journal of Respiratory Cell and Molecular Biology 2000, 22(1):4-7.
171. Shibata T., et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008, 135(4):1358-1368. 1368 e1351-e1354.
172. Shibata T., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(36):13,568-13,573.
173. Shim G.S., et al. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radical Biology and Medicine 2009, 47(11):1619-1631.
174. Shin S., et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. European Journal of Pharmacology 2009, 620(1-3):138-144.
175. Singh A., et al. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxidants & Redox Signaling 2010, 13(11):1627-1637.
176. Singh A., et al. Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs. Free Radical Biology and Medicine 2009, 46(3):376-386.
177. Singh A., et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Medicine 2006, 3(10):e420.
178. Sjoblom T., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274.
179. Slocum S.L., et al. Nrf2: control of sensitivity to carcinogens. Archives of Toxicology 2011, 85(4):273-284.
180. Snyder G.H., et al. Electrostatic influence of local cysteine environments on disulfide exchange kinetics. Biochemistry 1981, 20(23):6509-6519.
181. Sporn M.B., et al. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. Journal of Natural Products 2011, 74(3):537-545.
182. Stack C., et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology and Medicine 2010, 49(2):147-158.
183. Stewart D., et al. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. Journal of Biological Chemistry 2003, 278(4):2396-2402.
184. Strachan G.D., et al. Fetal Alz-50 clone 1 interacts with the human orthologue of the Kelch-like Ech-associated protein. Biochemistry 2004, 43(38):12,113-12,122.
185. Suh N., et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Research 1999, 59(2):336-341.
186. Sumi D., et al. Catechol estrogens mediated activation of Nrf2 through covalent modification of its quinone metabolite to Keap1. Journal of Toxicological Sciences 2009, 34(6):627-635.
187. Sussan T.E., et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(1):250-255.
188. Suzuki M., et al. Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology 2008, 39(6):673-682.
189. Taguchi K., et al. Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Molecular and Cellular Biology 2010, 30(12):3016-3026.
190. Taguchi K., et al. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011, 16(2):123-140.
191. Taira T., et al. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Reports 2004, 5(2):213-218.
192. Takahashi T., et al. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. Journal of Surgical Oncology 2010, 101(6):500-506.
193. Talalay P., et al. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 1988, 85(21):8261-8265.
194. Tanaka Y., et al. NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. Journal of Pharmacology and Experimental Therapeutics 2008, 325(2):655-664.
195. Tian F.F., et al. Nrf2-mediated protection against UVA radiation in human skin keratinocytes. Bioscience Trends 2011, 5(1):23-29.
196. Tiegs G., et al. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. Journal of Clinical Investigations 1992, 90(1):196-203.
197. Tong K.I., et al. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Molecular and Cellular Biology 2006, 26(8):2887-2900.
198. Tong K.I., et al. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biological Chemistry 2006, 387(10, 11):1311-1320.
199. Tong K.I., et al. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Molecular and Cellular Biology 2007, 27(21):7511-7521.
200. van Muiswinkel F.L., et al. The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Current Drug Targets CNS & Neurological Disorders 2005, 4(3):267-281.
201. von Otter M., et al. Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mechanisms of Ageing and Development 2010, 131(2):105-110.
202. Wakabayashi N., et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(7):2040-2045.
203. Wakabayashi N., et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nature Genetics 2003, 35(3):238-245.
204. Wakabayashi N., et al. Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Science Signaling 2010, 3(130):ra52.
205. Wang R., et al. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochemical and Biophysical Research Communications 2008, 373(1):151-154.
206. Wang X.J., et al. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(49):19,589-19,594.
207. Wang X.J., et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29(6):1235-1243.
208. Watai Y., et al. Subcellular localization and cytoplasmic complex status of endogenous Keap1. Genes Cells 2007, 12(10):1163-1178.
209. Williams T.N. Human red blood cell polymorphisms and malaria. Current Opinion in Microbiology 2006, 9(4):388-394.
210. Wong T.F., et al. Association of Keap1 and Nrf2 genetic mutations and polymorphisms With endometrioid endometrial adenocarcinoma survival. International Journal of Gynecological Cancer 2011, 21(8):1428-1435.
211. Wu J.H., et al. Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1. Chemical Biology & Drug Design 2010, 75(5):475-480.
212. Xu C., et al. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Research 2006, 66(16):8293-8296.
213. Yamamoto T., et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Molecular and Cellular Biology 2008, 28(8):2758-2770.
214. Yang M., et al. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Research and Treatment 2011, 129(3):983-991.
215. Yang W., et al. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Human Molecular Genetics 2007, 16(23):2900-2910.
216. Yates M.S., et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 2009, 30(6):1024-1031.
217. Yoh K., et al. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney International 2001, 60(4):1343-1353.
218. Yokota T., et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochemical and Biophysical Research Communications 2003, 312(4):1342-1348.
219. Yu S., et al. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One 2010, 5(1):e8579.
220. Yu Z., et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 2011, 54(4):922-934.
221. Yueh M.F., et al. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. Journal of Biological Chemistry 2007, 282(12):8749-8758.
222. Zhang D.D., et al. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Molecular and Cellular Biology 2003, 23(22):8137-8151.
223. Zhang D.D., et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Molecular and Cellular Biology 2004, 24(24):10941-10953.
224. Zhang D.D., et al. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. Journal of Biological Chemistry 2005, 280(34):30,091-30,099.
225. Zhang P., et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Molecular Cancer Therapeutics 2010, 9(2):336-346.
226. Zhang Y.K., et al. Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. Toxicology and Applied Pharmacology 2010, 245(3):326-334.
227. Zhao Z., et al. Age-related retinopathy in NRF2-deficient mice. PLoS One 2011, 6(4):e19,456.
228. Zhu M., et al. Functional characterization of transcription regulators that interact with the electrophile response element. Biochemical and Biophysical Research Communications 2001, 289(1):212-219.